Generating Evidence From Expanded Access Use of Rare Disease Medicines: Challenges and Recommendations

The authors present examples of clinical data generated from expanded access programs for rare disease medicines and discuss the ethical and regulatory considerations for using such data to inform regulator and payer decisions in the European Union and the US. They recommend that regulators issue new guidance on data collection during expanded access and update existing compassionate use guidance to better balance evidence generation with patient access.